US precision oncology company Boundless Bio (Nasdaq: BOLD) has announced financial results and business highlights for the fiscal quarter ended March 31, 2025.
Net loss totaled $15.8 million for the first quarter of 2025, compared to $15.4 for the same period in 2024. The company noted that its cash, cash equivalents, and short-term investments totaled $138.3 million as of March 31, 2025. Boundless’ share edged up 2% to $1.44 following the announcement.
The company also presented an update on its current research activities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze